Loading briefing details...
News Brief
By: PointLine Media Research & Editorial Team
Category:Business,Health,Industry,Science & Environment
November 5, 2026
This research provides a critical preclinical roadmap for mitigating cisplatin-induced nephrotoxicity, a major clinical hurdle in oncology. By identifying a multi-pathway natural intervention, the study opens new doors for developing supportive care strategies that could improve patient quality of life and potentially allow for more effective chemotherapy dosing.
A recent study published in Pediatric Discovery reveals that an aqueous extract of Phyllanthus urinaria (PU) offers significant protection against cisplatin-induced acute kidney injury (AKI). Cisplatin is a highly effective chemotherapy drug frequently limited by its severe nephrotoxic side effects, which affect nearly 30% of patients. By testing this natural extract in a murine model, researchers demonstrated that PU effectively mitigates renal damage, inflammation, and oxidative stress.
The experimental results show that PU treatment successfully lowers blood urea nitrogen and serum creatinine levels while preserving essential renal tubule structure. Through the suppression of pro-inflammatory cytokines and the modulation of apoptosis-related proteins, the extract helps rebalance cellular defenses. Furthermore, the study highlights that PU reinforces the NRF2/NQO1 antioxidant pathway, offering a multi-pathway mechanism to combat the toxicity typically associated with cisplatin administration.
While these preclinical findings provide a promising foundation for future nephroprotective strategies, the authors emphasize that this is not a clinical recommendation. Further research is necessary to identify active compounds, optimize therapeutic dosing, and ensure that kidney protection does not interfere with the drug's anticancer efficacy. This study represents a vital step toward developing supportive therapies that could improve safety and outcomes for patients undergoing chemotherapy.